Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
This article was originally published in The Pink Sheet Daily
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.
You may also be interested in...
Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.
As part of its burgeoning efforts in neuroscience, Genentech will discover and develop compounds and companion diagnostics for the treatment of pain, not an area the company historically has played in.